Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics. OMICS 2012 Mar;16(3):113-22
Date
03/10/2012Pubmed ID
22401657Pubmed Central ID
PMC3300066DOI
10.1089/omi.2011.0031Scopus ID
2-s2.0-84859788407 (requires institutional sign-in at Scopus site) 23 CitationsAbstract
Malignant gliomas are the most frequent type of primary brain tumors. Patients' outcome has not improved despite new therapeutics, thus underscoring the need for a better understanding of their genetics and a fresh approach to treatment. The lack of reproducibility in the classification of many gliomas presents an opportunity where genomics may be paramount for accurate diagnosis and therefore best for therapeutic decisions. The aim of this work is to identify large and focal copy number abnormalities (CNA) and loss of heterozygosity (LOH) events in a malignant glioma population. We hypothesized that these explorations will allow discovery of genetic markers that may improve diagnosis and predict outcome. DNA from glioma specimens were subjected to CNA and LOH analyses. Our studies revealed more than 4000 CNA and several LOH loci. Losses of chromosomes 1p and/or 19q, 10, 13, 14, and 22 and gains of 7, 19, and 20 were found. Several of these alterations correlated significantly with histology and grade. Further, LOH was detected at numerous chromosomes. Interestingly, several of these loci harbor genes with potential or reported tumor suppressor properties. These novel genetic signatures may lead to critical insights into diagnosis, classification, prognosis, and design of individualized therapies.
Author List
Assem M, Sibenaller Z, Agarwal S, Al-Keilani MS, Alqudah MA, Ryken TCAuthor
Mahfoud Assem PharmD Associate Professor in the School of Pharmacy Administration department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
FemaleGenomics
Glioma
Humans
In Vitro Techniques
Loss of Heterozygosity
Male
Middle Aged
Reverse Transcriptase Polymerase Chain Reaction
